Vice Chairman of Political Consultative Conference of Wenzhou Ouhai District Visited Jiangsu Vcare

Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Project Approved for Pivotal Phase II Clinical Trial

Recently, the pivotal Phase II clinical study for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 for treating NTRK fusion-positive solid tumors was approved by the NMPA. This clinical study will further evaluate the efficacy and safety of VC004 in patients with NTRK fusion mutations. Upon success, Jiangsu Vcare plans to submit an NDA in China.

View Details

Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Topical Gel Completes First Patient Dosing in Mild-to-Moderate Atopic Dermatitis Trial

Recently, the second-generation selective JAK1 inhibitor VC005 Topical Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), completed the first topical skin dosing in a patient with mild-to-moderate atopic dermatitis（AD）.

View Details

Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Completes First Patient Dosing in Phase II Clinical Trial for Moderate-to-Severe Atopic Dermatitis

Recently, the second-generation selective JAK1 inhibitor VC005 Tablet, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), completed the first patient dosing in its Phase II clinical trial for moderate-to-severe atopic dermatitis (AD).

View Details

Jiangsu Vcare Awarded "Jiangsu Provincial Science and Technology Award (Second Prize)"

In July, the Jiangsu Provincial Government announced the recipients of the 2022 Jiangsu Provincial Science and Technology Awards. Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), as a participating unit, jointly completed the project New Pharmaceutical Cocrystal Technology and Its Industrial Application with the research team of Zhang Jianjun and Gao Yuan from China Pharmaceutical University.

View Details

Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Tablet Completes First Patient Dosing in Phase II Clinical Trial for Ankylosing Spondylitis

The second-generation selective JAK1 inhibitor VC005 Tablet, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), recently initiated its Phase II clinical study for ankylosing spondylitis (AS). On April 26th, the first patient was successfully dosed at Peking University People's Hospital. VC005 Tablet demonstrated favorable metabolic properties, safety, and tolerability in the completed Phase I clinical study.

View Details

Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Gel Approved for Clinical Study in Mild-to-Moderate Atopic Dermatitis

Recently, the second-generation selective JAK1 inhibitor VC005 Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received approval from the NMPAto conduct clinical trials. The target indication is mild-to-moderate atopic dermatitis (AD). Related Phase I clinical trial work is scheduled to commence shortly.

View Details